Navigation Links
BioVex Agrees SPA With the FDA for a Pivotal Phase III Study With OncoVEX (GM-CSF) in Head and Neck Cancer
Date:9/15/2009

ession is responsible for the majority of deaths. The two year loco-regional failure rate following front line treatment is around 30% with a further 20% of patients progressing at a distant site. The long-term loco-regional control rate of 100% combined with the high percentage of patients that remain disease free at up to 40 months from treatment is very encouraging and provides confidence that OncoVEX (GM-CSF) will significantly reduce relapse rates as compared to standard therapy alone in the pivotal study recently agreed with the FDA."

About Head and Neck Cancer

Head and neck cancer accounts for 47,000 new cases (3% of all new cancer cases and 2% of all cancer deaths) in the United States annually; it is the fifth most common malignancy worldwide (an estimated 644,000 new cases annually).

Patients with locally advanced tumors are best treated with concurrent chemoradiation, with planned neck dissection indicated in certain patients. Despite aggressive treatment of locally advanced disease loco-regional recurrences develop in 30% of patients and distant metastases in 20%. Aggressive combined modality therapy may be frequently associated with debility, and numerous physical and psychological symptoms including pain, dysphagia, weight loss, disfigurement, depression, and xerostomia (dry mouth). As a result, new and improved, and less toxic therapies for head and neck cancer are urgently required.

About BioVex

BioVex is a privately held biotechnology company based in Woburn, MA where it also has an operational launch grade manufacturing facility. The Company is developing a new class of potent biologics for the treatment of cancer and prevention of infectious disease.

The Company's lead cancer technology platform, OncoVEX (GM-CSF) is a first-in-class oncolytic, or cancer destroying virus technology. OncoVEX (GM-CSF) designed to work by; repli
'/>"/>

SOURCE BioVex Inc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma
2. BioVex Raises $40 Million in First Close of Series F Financing
3. BioVex to Present at the UBS Global Life Sciences Conference
4. BioVex Closes Second Round of Series E Financing
5. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
6. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
7. CardioDynamics Agrees to be Acquired by SonoSite for $1.35 Per Share
8. MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant
9. PharmaNet Development Group Agrees to be Acquired by JLL Partners
10. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
11. Sosei Agrees Terms With ASKA for Commercialisation of SOH-075 (NorLevo(R))
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... , 27 avril 2015 /PRNewswire/ ... médicamenteuse spécialisée dans le développement d,une ... soigner les infections bactériennes polypharmacorésistantes potentiellement ... de données prouvant les promesses de ... dans la lutte contre la résistance ...
(Date:4/27/2015)... 27, 2015 SynGen Inc., a company that ... that harvest stem and progenitor cells from umbilical cord ... today that it has added three new members to ... Blood Business Units focus on product commercialization. ... its Vice President and Chief Financial Officer.  Chuck was ...
(Date:4/27/2015)... McKinney, Texas (PRWEB) April 27, 2015 ... products for use in applications such as animal ... fat and oil reduction in wastewater treatment plants ... be an exhibitor at the Texas Commission on ... May 5-6 in Austin, Texas. , The company ...
(Date:4/27/2015)... April 27, 2015 Diasome Pharmaceuticals, ... agreement with Joslin Diabetes Center (“Joslin”) to collaborate ... of Diasome’s novel Hepatocyte Directed Vesicle (“HDV”) targeting ... diabetes. , Located in Boston, Massachusetts, Joslin ... and education organization dedicated to the prevention, treatment ...
Breaking Biology Technology:TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 2TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 3TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 4TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 5TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 6SynGen Inc. Expands Its Management Team 2DryLet to Showcase Multiple Products at Texas Commission on Environmental Quality Trade Fair and Conference May 5-6 in Austin, Texas 2Diasome Pharmaceuticals Announces Clinical Trial Design Collaboration 2
... Canopus,BioPharma, Inc. (OTC: CBIA), has confirmed the ... reducing agent and has also demonstrated the,synergistic effect ... and,cetuximab (Erbitux) in two mice lung cancer models., ... stated, "We at,Canopus are encouraged with the discovery ...
... Dominica, June 19 Neuftec,Limited, the proprietor of ... recently issued a claim against Oxonica Energy,Limited, a ... of its,European Patent in the High Court of ... AGM Statement issued by Dr Matthews,(CEO) on 19 ...
... biopharmaceutical industry information on ... ... BioSpace, the world,s,leading online community for the bioscience industry, released ... devices industries in Asia. AsiaBio(TM) features dynamic,informational Hotbed Web pages ...
Cached Biology Technology:CB1400, Patented by Canopus BioPharma, Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erbitux). 2Neuftec Responds to a Fundamental Inaccuracy in Oxonica PLC's Regulatory Announcement 2BioSpace Announces New Online Community for Asia 2
(Date:4/10/2015)... 2015 Research and Markets ( ... "Security Competitive Profiles - NEC" report to their ... NEC will continue to supply a range of IT ... a company focus on the development of a Big ... opportunities in the Asia-Pacific region ...
(Date:4/2/2015)... , April 2, 2015 At its ... Salt Lake City , the American College of ... five new directors to its Board.  Members of the ... ACMG and for forming and advancing its policies and ... genetics profession. "It,s an eventful time in ...
(Date:3/31/2015)... March 31, 2015  Elephant Talk Communications Corp. (NYSE ... provider of Software Defined Network Architecture (ET Software DNA® ... revenue of approximately $20.4 million for the year ended ... million for the year ended December 31, 2013. ... Company had completed its multi-year transition away from its ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... has found that species living together are not forced ... challenging a theory that has held since Darwin,s Origin ... the most diverse bird families in the world, the ... of the processes causing species differences to evolve. ...
... , GAINESVILLE, Fla. --- Using the largest dated evolutionary ... suggests how plants developed traits to withstand low temperatures, ... bigger threat than initially thought to plants and global ... the journal Nature and co-authored by University ...
... scientists, chemical engineers and physicists from the University of Pennsylvania ... crystals as a medium for assembling structures. In their ... in the repeating patterns found in liquid crystals, in nanoscale ... pattern out of an even simpler template: a three-dimensional array ...
Cached Biology News:'Be different or die' does not drive evolution 2'Be different or die' does not drive evolution 3Study: Some plants may not adapt quickly to future climate change 2Study: Some plants may not adapt quickly to future climate change 3Penn researchers grow liquid crystal 'flowers' that can be used as lenses 2Penn researchers grow liquid crystal 'flowers' that can be used as lenses 3
PKC (pSer345), phospho-specific...
Anti-ADAMTS-4, disintegrin-like domain Immunogen: Synthetic peptide - KLH conjugated Available Date: 38569...
Rabbit polyclonal to Streptococcus Enterotoxin C ( Abpromise for all tested applications)....
... 100 g monoclonal antibody which can ... V from heart mitochondria. Also included are ... control immunocapture. The Complex V immunocapture kit ... (E.C. 3.6.3.14) from small amounts of tissue. ...
Biology Products: